We use essential cookies to run this site and, with your permission, analytics cookies to understand how it is used. You can change your mind at any time. See our Privacy Policy.
Clinical-grade diagnostics, monitoring, and intervention systems.
Chronic disease does not respect organ boundaries, and neither does the diagnostic gap. Select a system to see what the global evidence says.
In GBD 2021, conditions of the nervous system overtook cardiovascular disease as the single biggest contributor to global disease burden.
GBD 2021 Nervous System Disorders Collaborators, The Lancet Neurology, 2024. Summary via WHO and IHME.
India carries a cardiovascular mortality rate well above the global average, alongside a diabetes prevalence and air pollution exposure that compound it.
World Heart Federation, World Heart Observatory — India, drawing on IHME GBD, NCD Risk Factor Collaboration and WHO Global Health Observatory.
Chronic kidney disease is largely asymptomatic through its early stages. Mortality has risen faster than almost any other chronic condition since 1990.
GBD 2021 chronic kidney disease analyses. Prevalence estimates vary between 359M and 697M depending on staging definition — the figure shown is the GBD 2021 all-stage case count.
Progress against hepatitis B and C is being erased by metabolic and alcohol-related liver disease. Fatty liver is now the dominant driver of new cirrhosis.
GBD 2021 liver cirrhosis analysis, 1990–2021. Hepatitis B and C related cirrhosis declined over the same period while alcohol-related deaths rose.
Musculoskeletal conditions are the leading contributor to years lived with disability. Low back pain alone tops the global disability table.
World Health Organization musculoskeletal conditions fact sheet, drawing on GBD estimates. Figures are prevalence, not mortality.
Figures are drawn from published Global Burden of Disease and WHO estimates and are reproduced here for context, not as claims about any Mecklin product. Verify against the current release before republishing — GBD revises historic estimates with each cycle.
Across every organ system, early disease borrows the vocabulary of ordinary complaints — or produces no complaint at all. That is why people wait, and why the measurement that would have explained it was never taken.
Burning behind the breastbone after a heavy meal reads as heartburn. An antacid is taken, the discomfort dulls, and the episode is filed away as gas.
A racing heart, tight chest, breathlessness and a sense of dread describe a panic attack almost exactly. It also describes an arrhythmia, and the two are routinely confused in both directions.
Chronic kidney disease is largely silent through its early stages. Fatigue, poor sleep and swollen ankles get attributed to age or overwork, and function is often well below half before anyone looks.
Fatty liver disease typically produces nothing a patient would report. It is found incidentally on a scan ordered for something else — or not at all, until fibrosis is established.
A transient episode of weakness, slurred speech or vision loss resolves before anyone reaches a clinic. Nothing is recorded, and the warning that preceded a stroke goes unexamined.
Bone loss is painless. For many people the first evidence of osteoporosis is the fragility fracture itself — a diagnosis made after the damage rather than before it.
In India dial 112 or 108. Do not wait to take a reading, and do not drive yourself. In both heart attack and stroke, minutes of delay cost tissue permanently.
No device on this page can rule out an emergency. A normal ECG does not exclude a heart attack — a large share of acute myocardial infarctions show no diagnostic change on the first trace, which is why hospitals repeat the ECG and run troponin blood tests. The same logic applies across systems: a single normal reading is not an all-clear. Our systems are built to record what happens over time so a clinician has evidence to interpret. They support diagnosis. They never replace emergency care.
Both are useful. They answer different questions, carry different regulatory weight, and fail in different ways. Confusing them is how a normal reading gets mistaken for reassurance.
Answers: “Does something look off right now?”
Answers: “What happened, when, how often, and for how long?”
Atria® 21-Day is an ambulatory rhythm monitor. It is designed to capture and classify arrhythmia across a three-week window — not to diagnose myocardial infarction, and not for use in an emergency.
Three constraints put clinical measurement out of reach long before a diagnosis is ever missed.
A hospital-grade instrument stays in the hospital. The patient with intermittent symptoms, the pilgrim at altitude, the village three hours from a district centre — none of them are standing next to it when it matters.
A trace is only useful if someone can read it. Where cardiologists are scarce, the recording gets made and then waits. Classification has to move to the point of measurement, not the other way round.
Cloud-dependent diagnostics fail exactly where they are needed most. A device that requires bandwidth to reach a verdict is a device that does not work in the last mile.
One team owns the signal path from electrode to report. No hand-offs at bring-up, no vendor in the middle of the diagnosis.
Biopotential front-ends with sub-microvolt noise floors and defibrillator-grade isolation. Guard traces, isolated power planes and shielded analogue grounds are non-negotiable on every board we lay out.
Hardware division
A 238,000-parameter model quantised into roughly 5 KB, running on a Cortex-M alongside the acquisition loop. The verdict is reached where the measurement is taken — offline, and without a round trip.
Signal & data science
Encrypted transit, immutable audit trails, and FHIR R4 or HL7 v2 connectivity into existing EMR and LIMS. Automated classification arrives with its confidence and the underlying strip attached — interpretation stays with the clinician.
Software division
Every figure here comes from a board on a bench or a system in service — not a roadmap. We publish what we have actually delivered, and nothing we haven't.
The 21-day ambulatory monitor moves into evaluation with partner cardiology departments, under written agreements covering intended use, data handling and reporting obligations.
Read moreApplications filed covering our biopotential acquisition front-end across the device programmes. Under examination.
Read moreAn implantable neuromodulation programme targeting treatment-resistant depression and chronic migraine.
Read moreJoint work with hospitals and academic groups on signal datasets, model validation and study design.
Read moreAutonomous diagnostic kiosks built to run unattended on unreliable power and intermittent connectivity, bringing a panel of clinical parameters to places without a staffed pathology lab.
Read moreEngineering and clinical writing from the people doing the work. No press releases.
A walk through guard traces, isolated planes, and where the noise actually enters.
Read articleAt 90% analysable, fifty hours of a three-week study are missing, and nothing tells you which fifty.
Read articleOla matched Uber in a year. The reason sits in who pays for the first eight years of a technology.
Read articleA look at where the curve bends, and why three weeks became our design target.
Read articleWe build from Lucknow for conditions we can see: intermittent power, limited bandwidth, and clinics operating a long way from a tertiary centre. A system that holds up here holds up anywhere.
We hold no certifications or market authorisations at this time. Every pathway below is pending. We would rather be checkable than impressive.
Mecklin Research currently holds no certifications, accreditations or market authorisations. The frameworks listed above are the pathways our development is being aligned to; none has been completed or granted. No product described on this site is cleared or approved for commercial diagnostic use in any market, and nothing here should be read as a regulatory claim.
Different form factors. The same acquisition chain and the same on-device intelligence underneath. All three are in development — none is commercially available yet.
A single adhesive patch recording continuously for three weeks, with arrhythmia classification running on the patch itself. Applied once, worn through normal daily activity, returned by post.
An autonomous diagnostic kiosk bringing a panel of clinical parameters to places without a staffed pathology lab. Built to run unattended, on unreliable power and intermittent connectivity.
Encrypted video consultation with live vital streams from paired devices, so the clinician sees the measurement and the patient in the same session rather than reading a report afterwards.
Evaluate Atria in your department under a written agreement covering intended use and reporting.
Enquire about AtriaBring us a hardware or firmware problem. One scoping call with an engineer, and a plain answer on fit.
Technology divisionPublic health deployments, screening camps and district-scale rollouts of the Health ATM.
Talk to usAccess raw signal, model documentation and study support for collaborative clinical work.
Collaborate